DDReg pharma

Quailty Driven by Passion

Submit Query

Author name: development

ChatGPT Simplify Regulatory Affairs in Medical Devices

How LLMs like ChatGPT Can Simplify Regulatory Affairs for New Medical Devices

All Category, Blogs /

The European Union’s Medical Device Regulation (MDR) 2017/745 has significantly transformed the regulatory affairs landscape for medical device manufacturers by establishing strict requirements to ensure the safety and efficacy of devices before they reach the European market. These regulations demand detailed technical documentation, comprehensive clinical evaluations, and proactive post-market surveillance, creating substantial resource and time […]

How LLMs like ChatGPT Can Simplify Regulatory Affairs for New Medical Devices Read More »

Barriers medical device adverse event reporting

Identifying Barriers in Reporting Medical Device Adverse Effects

All Category, Blogs, Pharmacovigilance /

Medical Devices are an important part of the healthcare delivery system used in the diagnosis, monitoring, and management of diseases. Recent scientific innovations and technological solutions have expanded the use of medical devices globally. Medical devices can include items such as apparatus, instruments, appliances, substances, in-vitro reagents, software, etc. and other related objects used for

Identifying Barriers in Reporting Medical Device Adverse Effects Read More »

New Changes in EU Pharmaceutical Laws

Adapting to Changes in EU Pharmaceutical Laws

All Category, Blogs /

The European Union (EU) has long been recognized as a global leader in pharmaceutical legislation. In light of evolving healthcare needs, patient care, and technological advancements, the EU  amended 2 of their legislative frameworks on April 10th, 2024, named Directive on medicinal products for human use and the Regulation on authorisation and supervision of medicinal products for

Adapting to Changes in EU Pharmaceutical Laws Read More »

Role EMA Policy 0070 in Global Clinical Trials and Regulatory Practices

What EMA Policy 0070 Means for Global Clinical Trials and Regulatory Practices

All Category, Blogs /

In recent years, the pharmaceutical industry has been under increasing pressure to improve transparency, particularly when it comes to sharing clinical trial data. As the demand for open access to clinical research grows, regulatory bodies are stepping up to ensure that public health decisions are made based on comprehensive, accessible information. The European Medicines Agency

What EMA Policy 0070 Means for Global Clinical Trials and Regulatory Practices Read More »

DDReg in the News

DDReg in the News

All Category, News and Events /

The news of DDReg announcing its collaboration with Quantiphi has been featured in numerous leading news publications and media pages. This is an exciting chapter as it’s the first time Artificial Intelligence is going to be used in navigating regulatory complexities in the pharmaceutical and biotechnology landscape across the globe. Quantiphi, a global AI-first digital

DDReg in the News Read More »

Integrating Real-World Data into Regulatory Practices of Electronic Health Records and Medical Claims

All Category, Blogs, Pharmacovigilance /

As the healthcare and pharmaceutical industries increasingly turn to data-driven solutions, the integration of real-world data (RWD) into regulatory decision-making has emerged as a key focus for enhancing pharmaceutical practices. Utilizing data from Electronic Health Records (EHRs) and medical claims can provide valuable insights into patient care and treatment outcomes. This strategy has the potential

Integrating Real-World Data into Regulatory Practices of Electronic Health Records and Medical Claims Read More »

EU Updated SOHO Regulations in 2024

The Future of ATMPs under EU’s Updated SoHO Regulations

All Category, Blogs /

The Advanced Therapy Medicinal Products (ATMPs) regulation was and covers gene therapy, somatic cell therapy, and tissue-engineered products. The ATMP’s requirements for the development, manufacturing, approval, and post-marketing surveillance for these products are regulated under regulation (EC) No. 1394/2007 and Directive 2001/83/EC in the European Union (EU). Stringent regulatory agencies, like the European Medicines Agency

The Future of ATMPs under EU’s Updated SoHO Regulations Read More »

Navigating the New Requirements for Diversity in Clinical Trials

All Category, Blogs /

In recent years, the emphasis on diversity in clinical trials has become more prominent, reflecting the need for studies on more diverse populations to gather more accurate clinical findings. The lack of diversity in participants can create an obstacle to understanding the safety and efficacy of new medicines, making it more difficult to understand the

Navigating the New Requirements for Diversity in Clinical Trials Read More »

Guidance Nonclinical Development of Oligonucleotide

FDA’s First Draft Guidance on Nonclinical Development of Oligonucleotides

All Category, Insights, Regulatory /

The rapid evolution of biotechnology has positioned oligonucleotide-based therapeutics as one of the most promising therapeutic innovations in medicine today. From antisense oligonucleotides (ASOs) to small interfering RNAs (siRNAs) mRNA, and guide RNAs (gRNAs), these molecules are reshaping how we approach previously untreatable conditions. Recognizing the potential and complexity of this expanding area, and the

FDA’s First Draft Guidance on Nonclinical Development of Oligonucleotides Read More »

Key updates in ICH Q2 and Q14 guidelines for biologics

What Biologics Developers Need to Know about ICH Q2 and Q14 Revisions

All Category, Blogs /

The rapid advancement of biologics and the complexity of their development requires a meticulous approach to analytical procedures. With the revisions to the ICH Q2(R2) (Validation of Analytical Procedures) and the introduction of ICH Q14 (Analytical Procedure Development), biologics developers now have updated guidelines designed to address the unique challenges presented by these complex therapeutic

What Biologics Developers Need to Know about ICH Q2 and Q14 Revisions Read More »